ICU Medical, Inc. — 2013 Form 10-K
Reporting period: Fiscal year ended December 31, 2013. The filing also reports fourth-quarter results. ICU Medical develops and manufactures medical devices for infusion therapy, critical care and oncology, selling in more than 55 countries. It reports one operating segment.
Financial performance
| Metric | 2013 | 2012 | Change |
|---|---|---|---|
| Total revenue | $313.7 million | $316.9 million | Down 1% |
| Gross profit / margin | $154.7 million / 49% | $156.5 million / 49% | Margin unchanged |
| Operating income / margin | $51.9 million / 17% | $61.3 million / 19% | Down 15% |
| Net income | $40.4 million | $41.3 million | Down 2% |
| Diluted EPS | $2.65 | $2.80 | Down 5% |
| Cash from operations | $65.7 million | $66.3 million | Down slightly |
Fourth-quarter 2013 revenue was $77.9 million versus $82.7 million in Q4 2012; net income was $13.3 million versus $12.3 million. The filing reports annual gross margin of 49% in both years; operating margin fell as operating expenses increased.
At year-end, cash, cash equivalents and investments totaled $296.9 million, working capital was $367.4 million, and stockholders’ equity was $464.7 million. The balance sheet reports no borrowings; total current liabilities were $26.9 million. Capital expenditures were $18.4 million. ICU Medical paid no dividends and made no open-market share repurchases in 2013.
Material changes versus 2012
- Domestic sales fell 6% to $223.1 million, largely reflecting lower Hospira purchases. Sales to Hospira declined $12.9 million, or 11%, to $108.2 million; lower Clave sales accounted for much of the decrease.
- International sales increased 13% to $90.6 million, including a stated $1.5 million favorable effect from euro exchange rates.
- By product group, infusion therapy sales decreased 2% to $211.2 million; critical care decreased 7% to $51.5 million; oncology increased 24% to $37.5 million. Custom infusion-set sales rose, while Clave and critical-care sales declined.
- SG&A increased to $90.4 million from $84.6 million, including $1.8 million of medical-device excise tax and $1.4 million of costs for a strategic transaction that did not proceed. R&D increased to $12.4 million from $10.6 million.
- The effective tax rate fell to 23.3% from 33.2%, principally reflecting tax credits, foreign tax effects and tax items described in the filing; this moderated the decline in net income.
Outlook, risks and unusual items
- Management estimated 2014 capital expenditures of $18–24 million, including manufacturing capacity, equipment and IT. Completion of the Salt Lake City clean-room and manufacturing-space expansion was expected in the second half of 2014. Management stated existing liquidity and expected operating cash flow should fund operations for the next 12 months.
- Hospira represented 39% of 2013 revenue, and its agreements extend through 2018. ICU Medical cited Hospira’s reduced Clave orders and continued customer concentration as material risks.
- Other principal risks include competition and pricing pressure, upcoming Clave/MicroClave and Click Lock patent expirations beginning in 2014, reliance on manufacturing in Mexico and Slovakia, limited-source supplies, foreign-exchange exposure without hedging, and regulatory or product-liability risks.
- In a patent case against RyMed, the court ruled in September 2013 against ICU Medical on a prosecution-history-estoppel defense; the company was considering appeal or proceeding to damages. Management said other routine proceedings were not expected to materially affect results.
- New products introduced in 2013 included CardioFlo and ChemoLock. The company cautioned that successful commercialization and future growth were not assured. CEO Vivek Jain joined in February 2014; the filing was signed February 21, 2014.
- The 2013 statements include no legal-settlement or asset-sale gain, unlike 2011, when a $14.2 million gain from the Orbit product-line sale and a $2.5 million legal settlement were recorded. The independent auditor issued an unqualified opinion and reported effective internal control over financial reporting.
Investor facts to verify
- Whether Hospira’s purchasing patterns and distribution relationship stabilize, and how the company reduces its dependence on this customer.
- Whether international and oncology growth can offset declines in Clave and critical care, and whether new products gain commercial traction.
- The effect of patent expirations, competition and pricing pressure on Clave revenue, margins and customer retention.
- Whether planned capital investment is completed on schedule and yields expected production capacity and efficiency.
- How foreign-exchange, supplier, manufacturing-location and tax exposures develop; the filing reports no debt but identifies $5.5 million of gross unrecognized tax benefits.